Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -67.65% | 161.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -67.65% | 161.54% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -67.65% | 161.54% | |||
| SG&A Expenses | 23.39% | -3.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -96.85% | 25.20% | |||
| Total Operating Expenses | 22.19% | -1.94% | |||
| Operating Income | -22.25% | 1.99% | |||
| Income Before Tax | -330.51% | 2.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -330.51% | 2.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -330.51% | 2.68% | |||
| EBIT | -22.25% | 1.99% | |||
| EBITDA | -23.77% | 1.72% | |||
| EPS Basic | -294.25% | 3.07% | |||
| Normalized Basic EPS | -15.85% | 0.18% | |||
| EPS Diluted | -294.25% | 3.07% | |||
| Normalized Diluted EPS | -15.85% | 0.18% | |||
| Average Basic Shares Outstanding | 9.22% | 0.36% | |||
| Average Diluted Shares Outstanding | 9.22% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
